公开(公告)号：US20230279139A1

公开(公告)日：2023-09-07

申请号：US17686666

申请日：2022-03-04

Applicant: Development Center for Biotechnology

Inventor： Chun-Chung LEE ,  Yu-Hsun LO ,  Chu-Bin LIAO ,  Chen-Jei HONG ,  Sih-Yu CHEN ,  Yen-Yu WU ,  Szu-Liang LAI ,  Chih-Yung HU ,  Wen-Bin KE ,  Ya-Ting JUAN ,  Kao-Jean HUANG

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/622 ,  A61K2039/505

Abstract: The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

公开(公告)号：US11407757B2

公开(公告)日：2022-08-09

申请号：US16958721

申请日：2018-12-26

Applicant: Development Center for Biotechnology

Inventor： Shih-Chieh Yen ,  Chu-Bin Liao ,  Hui-Chen Wang ,  Po-Ting Chen ,  Yu-Chih Pan ,  Tsung-Hui Li ,  Bo-Rong Chen ,  Shian-Yi Chiou

IPC: C07D487/04 ,  A61P35/00

Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.

公开(公告)号：US11384150B2

公开(公告)日：2022-07-12

申请号：US16467655

申请日：2017-12-13

Applicant: Development Center for Biotechnology ,  Tunghai University

Inventor： Shih-Hsien Chuang ,  Wei-Ting Chao ,  Wei-Ting Sun ,  Hui-Jan Hsu ,  Wun-Huei Lin

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  A61K38/00 ,  A61K45/06 ,  A61K39/00 ,  A61K39/395

Abstract: An immunoconjugate, comprising an anti-EGFR antibody or a binding fragment thereof, and a kinase inhibitor.

公开(公告)号：US20210386866A1

公开(公告)日：2021-12-16

申请号：US17339747

申请日：2021-06-04

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： SHIH-HSIEN CHUANG ,  WEI-TING SUN ,  YING-SHUAN LAILEE ,  CHUN-LIANG LAI ,  WUN-HUEI LIN ,  WIN-YIN WEI ,  SHIH-CHONG TSAI ,  CHENG-CHOU YU ,  CHAO-YANG HUANG

IPC: A61K47/68 ,  A61K38/07 ,  A61K31/407 ,  A61K31/198 ,  A61K31/4745 ,  A61K47/54 ,  A61P35/00

Abstract: The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker, respectively; wherein the payload A and the payload B are the same or different. A pharmaceutical composition comprises the immunoconjugate and a method for treating cancer are also provided in the disclosure.

公开(公告)号：US20210139592A1

公开(公告)日：2021-05-13

申请号：US17256999

申请日：2019-07-14

Applicant: Development Center for Biotechnology

Inventor： Cheng-Chou YU ,  Shih-Rang YANG ,  Tsung-Han HSIEH ,  Mei-Chi CHAN ,  Shu-Ping YEH ,  Chuan-Lung HSU ,  Ling-Yueh HU ,  Chih-Lun HSIAO

IPC: C07K16/28 ,  A61K47/68

Abstract: An anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising: a heavy chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 2-4, 6-8, 10-12, 14-16, or 18-20; and/or a light chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 22-24, 26-28, 30-32, 34-36, or 38-40, wherein the antibody is a chimeric, humanized, composite, or human antibody.

公开(公告)号：US10947316B2

公开(公告)日：2021-03-16

申请号：US16010251

申请日：2018-06-15

Applicant: Development Center for Biotechnology

Inventor： Chao-Pin Lee ,  Shih-Hsien Chuang ,  Chuan-Lung Hsu ,  Yi-Jen Chen ,  Yu-Chin Nieh ,  Win-Yin Wei ,  Chia-Cheng Wu

IPC: A61P35/00 ,  A61K47/68 ,  A61K49/00 ,  G01N33/574 ,  A61K47/64 ,  A61K47/65 ,  A61K31/337 ,  A61K31/5365 ,  C07K16/30 ,  A61K39/395 ,  C07K16/28

Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab−(L−D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.

公开(公告)号：US20200048365A1

公开(公告)日：2020-02-13

申请号：US15988875

申请日：2018-05-24

Applicant: Development Center for Biotechnology

Inventor： Chia-Cheng Wu ,  Szu-Liang Lai ,  Yu-Jung Chen ,  Chih-Yung Hu ,  Tzu-Yin Lin

IPC: C07K16/34

Abstract: A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX′SGNRRYZLV (SEQ ID NO:7, wherein X′ is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

公开(公告)号：US20190330376A1

公开(公告)日：2019-10-31

申请号：US16475121

申请日：2017-12-29

Applicant: Development Center for Biotechnology

Inventor： Chen-Li Chien ,  Gregory Jiann Chen ,  Chuan-Lung Hsu ,  Jei-Hwa Yu ,  Hsien-Yu Tsai ,  Show-Shan Sheu ,  Wei-Jung Chang ,  Chia-Cheng Wu

IPC: C07K16/46 ,  C07K14/745

Abstract: A recombinant protein drug includes a parent protein drug coupled with a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO:2 or a homolog having a sequence identity of 80% or higher. The parent protein drug is a bispecific antibody having a first targeting domain linked by a bridging domain with a second targeting domain. The modified kininogen-1 peptide is fused between the first targeting domain and the bridging domain, or between the bridging domain and the second targeting domain. A method for increasing the serum half-life of a protein drug includes constructing a fusion protein comprising the protein drug coupled with a modified kininogen-1 peptide.

公开(公告)号：US20190309092A1

公开(公告)日：2019-10-10

申请号：US16318615

申请日：2017-07-20

Applicant: DCB-USA LLC ,  Development Center for Biotechnology

Inventor： Chih-Yung HU ,  Chao-Yang HUANG ,  Yu-Jung CHEN ,  Chia-Cheng WU ,  Chien-Tsun KUAN ,  Chia-Hsiang LO ,  Hsien-Yu TSAI

IPC: C07K16/46 ,  C07K16/18 ,  C07K16/30 ,  C07K16/22 ,  C07K16/28 ,  C07K16/24 ,  C07K16/32

Abstract: The present invention provides a modified antigen-binding Fab fragment. An antigen-binding molecule comprising the antigen-binding Fab fragment and a composition comprising the molecule are also provided.

公开(公告)号：US20190194686A1

公开(公告)日：2019-06-27

申请号：US16147741

申请日：2018-09-29

Applicant: Development Center for Biotechnology

Inventor： HSIN-LIN LU ,  CHIEN-I LIN ,  CHAO-YI TENG

IPC: C12N15/85 ,  C12N15/113

CPC classification number: C12N15/85 ,  C12N15/113 ,  C12N2015/8518

Abstract: A host cell for protein expression having a lower expression level of a gene, as compared to a wild-type cell, wherein the gene is selected from HDAC8, Dab2, Caspase3, Sys1, Ergic3, Grasp, Trim 23, or a combination thereof. The host cells are CHO cells. The lower expression level of the gene results from RNA interference, which may be achieved by transfecting a vector that contains an shRNA targeting the gene.